The global companion animal vaccine market is anticipated to reach valuation of ~USD 4,475 million by 2028, representing a CAGR of 5.6% from 2022 to 2028 as per the latest report by Gen Consulting Company.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global companion animal vaccine market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the companion animal vaccine industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the technology, animal type, and region. The global market for companion animal vaccine can be segmented by technology: attenuated vaccines (LAV), inactivated vaccines, recombinant vaccines, toxoid vaccines, others. The attenuated vaccines segment held the largest revenue share in 2021. Companion animal vaccine market is further segmented by animal type: cats, dogs, others. Among these, the dogs segment was accounted for the highest revenue generator in 2021. Based on region, the companion animal vaccine market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). North America captured the largest share of the market in 2021.

Market Segmentation
By technology: attenuated vaccines (LAV), inactivated vaccines, recombinant vaccines, toxoid vaccines, others
By animal type: cats, dogs, others
By region: Asia Pacific, Europe, North America, Rest of the World (RoW)

The market research report covers the analysis of key stake holders of the global companion animal vaccine market. Some of the leading players profiled in the report include Bioveta a.s., Boehringer Ingelheim International GmbH, Durvet, Inc., Elanco Animal Health Incorporated, HIPRA, S.A., Indian Immunologicals Ltd (IIL), Inner Mongolia Jinyu Group Co., Ltd., Merck & Co., Inc., Pulike Biological Engineering, Inc., Tianjin Ringpu Bio-technology Co., Ltd., Virbac New Zealand Ltd., Zoetis Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global companion animal vaccine market.
– To classify and forecast the global companion animal vaccine market based on technology, animal type, region.
– To identify drivers and challenges for the global companion animal vaccine market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global companion animal vaccine market.
– To identify and analyze the profile of leading players operating in the global companion animal vaccine market.

Why Choose This Report
– Gain a reliable outlook of the global companion animal vaccine market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.